NCT07184437 - A Clinical Investigation of MINIVISC® PLUS 14 mg/ml Fermented Ophthalmic Viscosurgical Device (OVD-F), Used for Cataract Surgery and Implantation of Intraocular Lenses, Glaucoma Surgery, Anterior Segment Surgery and Corneal Transplantation (CGAC) | Biotech Hunter

Enrollment

134

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

June 19, 2025

Study Completion Date

July 29, 2025

Conditions

Cataract

Interventions

DEVICE

OVD-F device Minivisc®PLUS 14 mg/ml

MINIVISC® PLUS 14 mg/ml is intended to protect, lubricate and support delicate ophthalmic cells or tissues, to assist in maintaining intraocular space and to enhance visualization during surgery.

Trial Locations (6)

3000

UZ Leuven, Leuven

791 82

Eye Clinic Falu Hosptal, Falun

113 22

Ögonläkargruppen Odenplan, Stockholm

183 34

Optalmica Eye Clinic, Stockholm

451 53

Optalmic Clinic Uddevalla Hospital, Uddevalla

581 85

Opthalmic Clinic University Hospital Linköping, Linköping